cjc-1295 ipamorelin long term side effects CJC-1295/Ipamorelin General Info Sheet CJC-1295 / Ipamorelin Peptide Therapy:
Description
Parkinsons disease developed in 20,895 of 6,098,405 subjects (0.34%)
doi: 10.1002/ajmg.c.30087

Le Maitre CL, Freemont AJ, Hoyland JA

Cell Death Dis 2018;9:536